Clinical trials: Disorders of Balance
Immunogenicity, Healthy Volunteers
Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Intas Pharmaceuticals Ltd.
- Trial name
- NCT04015232
- Testing
- INTP5, US Neulasta
- Where
- India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Intas Pharmaceuticals, Ltd.
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects, Apathy
Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers
This is a phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers.
- Trial name
- NCT06699628
- Testing
- IRL757
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Integrative Research Laboratories AB
Sleep, Obesity
Impact of Sleep Restriction on Performance in Adults
The overall goal of this project is to look at the effects of long-term, sustained sleep restriction (SR) in adults, and assess the effects on mood and cognitive and physical performance.
- Conditions
- Sleep, Obesity, Sleep Restriction
- Trial name
- NCT02960776
- Testing
- Sleep Restriction (SR)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Columbia University
Anxiety Disorders
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
This study will be conducted to evaluate and compare the single oral dose bioavailability of Paroxetine manufactured by GlaxoSmithKline (GSK) Pharmaceuticals S.A. for GlaxoSmithKline México, S.A. de C.V.
- Trial name
- NCT04311463
- Testing
- Paroxetine hydrochloride, PAXIL (Paroxetine hydrochloride )
- Where
- Mexico
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
Antifungal Agents
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
Griseofulvin is an antifungal agent used in treatment of Dermatophytosis caused by Microsporum spp. (species), Trichophyton spp., Epidermophyton spp., where topical therapy is considered inappropriate or has failed.
- Trial name
- NCT04318535
- Testing
- Griseofulvin 500 mg, Griseofulvin 250 mg, Reference Griseofulvin 500 mg
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ambulation Difficulty, Gait, Unsteady
The Sensorimotor Locus of Balance Control in Elderly Gait
The aging population is at an exceptionally high risk of debilitating falls, contributing significantly to reduced independence and quality of life.
- Conditions
- Ambulation Difficulty, Gait, Unsteady, Fall, Position Sense Disorders
- Trial name
- NCT03341728
- Testing
- Optical flow perturbations, Normal walking
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Obesity
Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation
T-PA release is impaired in obese subjects. In order to have a better mechanistic understanding of t-PA release, we will compare t-PA release to Flow Mediated Vasodilation, Radial Artery Tonometry, and other markers of…
- Trial name
- P1A3B (NCT00780481)
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Dizziness, Brain Injury
Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI)
The purpose of this project is to determine the effects of mild traumatic brain injury and blast exposure on the inner ear balance and central nervous systems.
- Trial name
- NCT01021137
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Intestinal Diseases
Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions
The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants. Researchers will compare the extent and rate to which the drug is absorbed.
- Trial name
- NCT06201559
- Testing
- Albendazole IP 400 mg, Albendazole 400 mg
- Where
- India
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dry Eye
Subjective and Objective Performance of Systane Complete Multi-Dose PF Versus Walgreen's Lubricant Balance
Single site, prospective, double-masked, randomized-controlled, two-arm study of the dry eye symptoms as well as corneal and conjunctival staining in subjects using 2 different eyedrops.
- Trial name
- NCT06219577
- Testing
- Systane Complete Multi-Dose PF, Walgreen's Lubricant Balance
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Scripps Poway Eyecare and Optometry
Stroke
Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals
aim: To examine the effect of a perturbation-based balance training on balance reaction characteristics in post stroke individuals.
- Trial name
- NCT02619175
- Testing
- Stroke Subjects Perturbation-Based Balance Training, Stroke Subjects Weight Shifting and Gait training
- Where
- Israel
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Nachum Soroker, MD
Traumatic Brain Injury (TBI)
Effect of Exercise Training on Physical, Cognitive, and Behavioral Function in People With TBI
Background: Traumatic brain injury (TBI) often causes problems with moving and balance, and thinking and emotions. Exercise can improve these things in people with other brain damage.
- Trial name
- NCT02504866
- Testing
- Vigorous exercise, Light to moderate exercise
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Metabolic Syndrome
Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome
Test the hypothesis that nebivolol treatment improves fibrinolytic balance and insulin sensitivity compared to metoprolol treatment in individuals with metabolic syndrome.
- Trial name
- NCT00775671
- Testing
- Nebivolol, Metoprolol
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus, Type 2
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
This is an open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of OXEMET™ 1000 mg coated tablets, relative to 1000 mg of the reference product administered as two 500 mg tablets, under…
- Trial name
- NCT01842620
- Testing
- Metformin
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
- Trial name
- NCT05286281
- Testing
- PF-07265803
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.
- Trial name
- NCT00944450
- Testing
- Sitagliptin phosphate anhydrous formulation, Comparator: sitagliptin phosphate monohydrate form
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Autoimmune Diseases, Fibrosis
Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025
Human, absorption, metabolism and excretion study of belumosudil (KD025)
- Trial name
- KD025-108 (NCT03907540)
- Testing
- Belumosudil 200 mg tablet, [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose, [14C]-KD025 200 mg capsule
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kadmon Corporation, LLC
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer